Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Philip, Mease"'
Autor:
Arthur Kavanaugh, Philip Mease, Laure Gossec, Roberto Ranza, Shigeyoshi Tsuji, Kevin Douglas, Michael Lane, Ralph Lippe, Manish Mittal, Tianming Gao, Arathi Setty, Sandra Ciecinski, Daniel Aletaha, Peter Nash
Publikováno v:
ACR Open Rheumatology, Vol 6, Iss 11, Pp 736-745 (2024)
Objective We explored the relationship between achievement of clinical disease control and improvements in and normative values for patient‐reported outcomes (PROs), including quality of life (QoL) measures, in patients with psoriatic arthritis (Ps
Externí odkaz:
https://doaj.org/article/68885dcde7f34e47b390d4e348fea563
Autor:
Philip Mease, Tatiana Korotaeva, Pavel Shesternya, Muza Kokhan, Anton Rukavitsyn, Dmitry Vasilchenkov, Mohamed Sharaf, Frédéric Lavie, Atul Deodhar
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 6, Pp 1551-1567 (2024)
Abstract Introduction There are limited data on the use of advanced therapies to treat psoriatic arthritis (PsA) in Russia. Guselkumab, an interleukin (IL)-23p19-subunit inhibitor, demonstrated efficacy in patients with PsA in the phase 3 DISCOVER-1
Externí odkaz:
https://doaj.org/article/45579ebd45974493ad26516b7a01fa05
Autor:
Jessica A. Walsh, Iris Lin, Ruizhi Zhao, Natalie J. Shiff, Laura Morrison, Bruno Emond, Louise H. Yu, Samuel Schwartzbein, Patrick Lefebvre, Dominic Pilon, Soumya D. Chakravarty, Philip Mease
Publikováno v:
Drugs - Real World Outcomes, Vol 11, Iss 3, Pp 487-499 (2024)
Abstract Background Treatment persistence among patients with psoriatic arthritis (PsA) is essential for achieving optimal treatment outcomes. Guselkumab, a fully human interleukin-23p19-subunit inhibitor, was approved by the United States (US) Food
Externí odkaz:
https://doaj.org/article/5984faa752c244f89c78d0606e965338
Autor:
Kurt de Vlam, Walter P. Maksymowych, Gaia Gallo, Proton Rahman, Philip Mease, Venkatesh Krishnan, Conor J. McVeigh, Jeffrey Lisse, Danting Zhu, Rebecca J. Bolce, Philip G. Conaghan
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 691-707 (2024)
Abstract Introduction The objective of this analysis is to evaluate the improvement in spinal pain with ixekizumab, placebo, and adalimumab based on objective measures of inflammation response in patients with ankylosing spondylitis (AS). Methods The
Externí odkaz:
https://doaj.org/article/eb8f53ffcf3f4cc2b2c455d755a35ab8
Autor:
Kurt de Vlam, Walter P. Maksymowych, Gaia Gallo, Proton Rahman, Philip Mease, Venkatesh Krishnan, Conor J. McVeigh, Jeffrey Lisse, Danting Zhu, Rebecca J. Bolce, Philip G. Conaghan
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 4, Pp 1063-1063 (2024)
Externí odkaz:
https://doaj.org/article/f8ef4c01d90e4cb1a780a59d216f6584
Autor:
Philip Mease, Désirée van der Heijde, Bruce Kirkham, Georg Schett, Ana-Maria Orbai, Christopher Ritchlin, Joseph F. Merola, Luminita Pricop, David A. James, Xuan Zhu, Gregory Ligozio
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background Psoriatic arthritis (PsA) patient data from two phase 3 secukinumab trials (FUTURE 1, 5) were analysed to quantify the prevalence and extent of pre-existing radiographic damage (RD) at baseline; investigate the association of RD w
Externí odkaz:
https://doaj.org/article/88cfee0faae741c196f42420661bb5fc
Autor:
Philip Mease, Atul Deodhar
Publikováno v:
BMC Musculoskeletal Disorders, Vol 23, Iss 1, Pp 1-11 (2022)
Abstract Background Optimal treatment of nonradiographic axial spondyloarthritis depends on accurate and timely diagnosis of the underlying disease; however, patients present with common symptoms that, in the absence of radiographic changes, may conf
Externí odkaz:
https://doaj.org/article/88cee48aa92f47e9884f0c1c3c571d05
Autor:
Dafna D Gladman, Lihi Eder, Vibeke Strand, David Gruben, Alexis Ogdie, Ari Polachek, Philip Mease, Sibel Z Aydin, Cassandra Kinch, Remy A Pollock, Rayana Luna, Mary Jane Cadatal
Publikováno v:
RMD Open, Vol 9, Iss 1 (2023)
Background Evaluate the impact of sex on tofacitinib efficacy, safety and persistence (time to discontinuation) in patients with psoriatic arthritis (PsA).Methods Data were pooled from two phase 3 randomised controlled trials. Patients were randomise
Externí odkaz:
https://doaj.org/article/0eae573dacbc4459a2ce54a3fc3c13a1
Autor:
Karamarie Fecho, Chris Bizon, Tursynay Issabekova, Sierra Moxon, Anne E. Thessen, Shervin Abdollahi, Sergio E. Baranzini, Basazin Belhu, William E. Byrd, Lawrence Chung, Andrew Crouse, Marc P. Duby, Stephen Ferguson, Aleksandra Foksinska, Laura Forero, Jennifer Friedman, Vicki Gardner, Gwênlyn Glusman, Jennifer Hadlock, Kristina Hanspers, Eugene Hinderer, Charlotte Hobbs, Gregory Hyde, Sui Huang, David Koslicki, Philip Mease, Sandrine Muller, Christopher J. Mungall, Stephen A. Ramsey, Jared Roach, Irit Rubin, Shepherd H. Schurman, Anath Shalev, Brett Smith, Karthik Soman, Sarah Stemann, Andrew I. Su, Casey Ta, Paul B. Watkins, Mark D. Williams, Chunlei Wu, Colleen H. Xu, The Biomedical Data Translator Consortium
Publikováno v:
Journal of Clinical and Translational Science, Vol 7 (2023)
Knowledge graphs have become a common approach for knowledge representation. Yet, the application of graph methodology is elusive due to the sheer number and complexity of knowledge sources. In addition, semantic incompatibilities hinder efforts to h
Externí odkaz:
https://doaj.org/article/8d108ce3ebbb408b85a7a73670319e07
Autor:
Atul Deodhar, Philip Mease, Helena Marzo-Ortega, Theresa Hunter, David Sandoval, Andris Kronbergs, Steven Lauzon, Ann Leung, Victoria Navarro-Compán
Publikováno v:
BMC Rheumatology, Vol 5, Iss 1, Pp 1-9 (2021)
Abstract Background Patients with non-radiographic axial spondyloarthritis experience negative impacts on sleep, work productivity, and activity impairment. Ixekizumab, a monoclonal antibody selectively targeting interleukin-17A, has shown efficacy i
Externí odkaz:
https://doaj.org/article/afcea2ea038a4b2ca540ae5a6aed7cc9